🎉 M&A multiples are live!
Check it out!

Armata Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Armata Pharmaceuticals and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Armata Pharmaceuticals Overview

About Armata Pharmaceuticals

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.


Founded

1989

HQ

United States of America
Employees

66

Financials

LTM Revenue $5.5M

LTM EBITDA -$45.5M

EV

$194M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Armata Pharmaceuticals Financials

Armata Pharmaceuticals has a last 12-month revenue of $5.5M and a last 12-month EBITDA of -$45.5M.

In the most recent fiscal year, Armata Pharmaceuticals achieved revenue of n/a and an EBITDA of -$65.4M.

Armata Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Armata Pharmaceuticals valuation multiples based on analyst estimates

Armata Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $5.5M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$65.4M -$44.1M XXX XXX XXX
EBITDA Margin -Infinity% -802% XXX XXX XXX
Net Profit -$23.2M -$36.9M XXX XXX XXX
Net Margin -Infinity% -671% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Armata Pharmaceuticals Stock Performance

As of March 17, 2025, Armata Pharmaceuticals's stock price is $2.

Armata Pharmaceuticals has current market cap of $70.6M, and EV of $194M.

See Armata Pharmaceuticals trading valuation data

Armata Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$194M $70.6M XXX XXX XXX XXX $-1.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Armata Pharmaceuticals Valuation Multiples

As of March 17, 2025, Armata Pharmaceuticals has market cap of $70.6M and EV of $194M.

Armata Pharmaceuticals's trades at 35.2x LTM EV/Revenue multiple, and -4.3x LTM EBITDA.

Analysts estimate Armata Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Armata Pharmaceuticals and 10K+ public comps

Armata Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $194M XXX XXX XXX
EV/Revenue 35.2x XXX XXX XXX
EV/EBITDA -4.4x XXX XXX XXX
P/E -2.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Armata Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Armata Pharmaceuticals Valuation Multiples

Armata Pharmaceuticals's NTM/LTM revenue growth is n/a

Armata Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Armata Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Armata Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Armata Pharmaceuticals and other 10K+ public comps

Armata Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -802% XXX XXX XXX XXX
EBITDA Growth -33% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -802% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Armata Pharmaceuticals Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Protalix XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Armata Pharmaceuticals M&A and Investment Activity

Armata Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Armata Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Armata Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Armata Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Armata Pharmaceuticals

When was Armata Pharmaceuticals founded? Armata Pharmaceuticals was founded in 1989.
Where is Armata Pharmaceuticals headquartered? Armata Pharmaceuticals is headquartered in United States of America.
How many employees does Armata Pharmaceuticals have? As of today, Armata Pharmaceuticals has 66 employees.
Who is the CEO of Armata Pharmaceuticals? Armata Pharmaceuticals's CEO is Dr. Deborah L. Birx, M.D..
Is Armata Pharmaceuticals publicy listed? Yes, Armata Pharmaceuticals is a public company listed on ASE.
What is the stock symbol of Armata Pharmaceuticals? Armata Pharmaceuticals trades under ARMP ticker.
When did Armata Pharmaceuticals go public? Armata Pharmaceuticals went public in 1994.
Who are competitors of Armata Pharmaceuticals? Similar companies to Armata Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Armata Pharmaceuticals? Armata Pharmaceuticals's current market cap is $70.6M
What is the current revenue of Armata Pharmaceuticals? Armata Pharmaceuticals's last 12-month revenue is $5.5M.
What is the current EBITDA of Armata Pharmaceuticals? Armata Pharmaceuticals's last 12-month EBITDA is -$45.5M.
What is the current EV/Revenue multiple of Armata Pharmaceuticals? Current revenue multiple of Armata Pharmaceuticals is 35.2x.
What is the current EV/EBITDA multiple of Armata Pharmaceuticals? Current EBITDA multiple of Armata Pharmaceuticals is -4.3x.
Is Armata Pharmaceuticals profitable? Yes, Armata Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.